CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, May 2015

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES

Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. Hajarizadeh B1, Grady B2, Page K3, et al. PLoS One. 2015 Apr 2;10(4):e0122232. doi: 10.1371/journal.pone.0122232. eCollection 2015.

=Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy. Akpo EI1, Cerri K, Kleintjens J. Pharmacoeconomics. 2015 Apr;33(4):409-22. doi: 10.1007/s40273-014-0249-4.

Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. Takayama K1, Furusyo N1, Ogawa E1, et al. World J Gastroenterol. 2015 Apr 21;21(15):4696-706. doi: 10.3748/wjg.v21.i15.4696.

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. Flamm SL1, Muir AJ, Fried MW, et al. J Clin Gastroenterol. 2015 Apr;49(4):336-44. doi: 10.1097/MCG.0000000000000150.

The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. Kan T1, Hashimoto S, Kawabe N, et al. Gastroenterol. 2015 Apr 24. [Epub ahead of print]

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial. Zeuzem S, Ghalib R, Reddy KR, et al. Ann Intern Med. 2015 Apr 24. doi: 10.7326/M15-0785. [Epub ahead of print]

Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Nguyen LT1, Gray E, Dean J, Carr M, et al. Antivir Ther. 2015 Apr 29. doi: 10.3851/IMP2964. [Epub ahead of print]

Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. Ahn SB1, Jun DW2, Kim SG3, et al. Eur J Intern Med. 2015 May;26(4):292-6. doi: 10.1016/j.ejim.2015.03.011. Epub 2015 Apr 13.

HCV-specific lymphocyte responses in individuals with positive anti-HCV but negative HCV-RNA. Sili U1, Kaya A2, Aydin S2, et al. J Clin Virol. 2015 Jun;67:73-7. doi: 10.1016/j.jcv.2015.04.014. Epub 2015 Apr 15.

Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study. Sise ME1, Backman ES2, Wenger JB1, et al. PLoS One. 2015 Apr 29;10(4):e0124139. doi: 10.1371/journal.pone.0124139. eCollection 2015.

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR). Trussoni CE1, Tabibian JH1, Splinter PL1, O’Hara SP1. PLoS One. 2015 Apr 27;10(4):e0125793. doi: 10.1371/journal.pone.0125793. eCollection 2015.

Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins. Kazakov T1, Yang F1, Ramanathan HN1, et al. PLoS Pathog. 2015 Apr 13;11(4):e1004817. doi: 10.1371/journal.ppat.1004817. eCollection 2015.

EFTUD2 is a novel innate immune regulator restricting hepatitis C virus infection through the RIG-I/MDA5 pathway. Zhu C1, Xiao F2, Hong J3, et al. J Virol. 2015 Apr 15. pii: JVI.00364-15. [Epub ahead of print]

Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. Petit MA1, Berthillon P2, Pradat P3, et al. Clin Res Hepatol Gastroenterol. 2015 Apr 17. pii: S2210-7401(15)00075-3. doi: 10.1016/j.clinre.2015.03.002. [Epub ahead of print]

Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. Hiet MS1, Bauhofer O1, Zayas M1, et al. J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00298-6. doi: 10.1016/j.jhep.2015.04.015. [Epub ahead of print]

MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein. Li M1, Wang Q1, Liu SA1, et al. World J Gastroenterol. 2015 Apr 21;21(15):4517-25. doi: 10.3748/wjg.v21.i15.4517.

Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Catanese MT1, Dorner M2. Virology. 2015 May;479-480C:221-233. doi: 10.1016/j.virol.2015.03.014. Epub 2015 Apr 4.

F protein increases CD4+CD25+ T cell population in patients with chronic hepatitis C. Hashempour T1, Bamdad T2, Bergamini A3, et al. Pathog Dis. 2015 Jun;73(4). pii: ftv022. doi: 10.1093/femspd/ftv022. Epub 2015 Apr 9.

Modeling and analysis of innate immune responses induced by the host cells against hepatitis C virus infection. Obaid A1, Ahmad J, Naz A, et al. Integr Biol (Camb). 2015 May 11;7(5):544-59. doi: 10.1039/c4ib00285g. Epub 2015 Apr 7.

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent. Kwon HJ1, Xing W1, Chan K1, et al. PLoS One. 2015 Apr 9;10(4):e0122844. doi: 10.1371/journal.pone.0122844. eCollection 2015.

HIV/HCV COINFECTION

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Kaur K1, Gandhi MA, Slish J. Infect Dis Ther. 2015 Apr 21. [Epub ahead of print]

Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. Grint D1, Peters L, Rockstroh JK, et al. AIDS. 2015 Apr 13. [Epub ahead of print]

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. Neukam K1, Munteanu DI2, Rivero-Juárez A3, et al. PLoS One. 2015 Apr 29;10(4):e0125080. doi: 10.1371/journal.pone.0125080. eCollection 2015.

Injection drug use and Hepatitis C as risk factors for mortality in HIV-infected indivi-duals: the Antiretroviral Therapy Cohort Collaboration. May MT1, Justice AC, Birnie K, et al. J Acquir Immune Defic Syndr. 2015 Apr 3. [Epub ahead of print]

Association of HIV, hepatitis C virus and liver fibrosis severity with intreleukin-6 and C-reactive protein levels. Shah S1, Ma Y, Scherzer R, Huhn G, et al. AIDS. 2015 Apr 13. [Epub ahead of print]

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Calza L1, Danese I, Colangeli V, et al. Infect Dis (Lond). 2015 Apr 15:1-12. [Epub ahead of print]

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. Rodriguez-Torres M1, Gaggar A, et al. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):543-9. doi: 10.1097/QAI.0000000000000516.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals. Gras L, de Wolf F, Smit C, et al. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

Prevalence and risk factors for patient-reported joint pain among patients with HIV/ Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection. Ogdie A1, Pang WG2, et al. BMC Musculoskelet Disord. 2015 Apr 19;16:93. doi: 10.1186/s12891-015-0552-z.

A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. Hodowanec AC1,2, Lee RD3, et al. BMC Infect Dis. 2015 Apr 17;15(1):190. [Epub ahead of print]

The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. Kramer JR1, Kowalkowski MA, Duan Z, Chiao EY. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):456-62. doi: 10.1097/QAI.0000000000000494.

Single nucleotide polymorphisms of CXCL9-11 chemokines are associated with liver fibrosis in HIV/HCV-coinfected patients. Pineda-Tenor D1, Berenguer J, García-Álvarez M, et al. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):386-95. doi: 10.1097/QAI.0000000000000491.

COMPLEMENTARY AND ALTERNATIVE MEDICINE

EPIDEMIOLOGY, DIAGNOSTICS, AND MISCELLANEOUS WORKS

Implementing Updated Recommendations on Hepatitis C Virus Screening: Translating Federal Guidance Into State Practice. Martin EG1, Norcott AM, Khalid H, OʼConnell DA. J Public Health Manag Pract. 2015 Apr 22. [Epub ahead of print]

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. Le TK1, Kalsekar A, Macaulay D, et al. J Manag Care Spec Pharm. 2015 Apr;21(4):308-18.

Hepatitis C virus reinfection and spontaneous clearance of reinfection – the InC3 study. Sacks-Davis R1, Grebely J2, Dore GJ2, et al. J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print]

Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. Backus LI1, Belperio PS, Shahoumian TA, Mole LA. J Clin Gastroenterol. 2015 Apr;49(4):329-35. doi: 10.1097/MCG.0000000000000124.

A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. Nguyen JT1, Rich JD, Brockmann BW, Vohr F, Spaulding A, Montague BT. J Urban Health. 2015 Apr 1. [Epub ahead of print]

Extrahepatic manifestations in chronic hepatitis C virus carriers. Rosenthal E1, Cacoub P2. Lupus. 2015 Apr;24(4-5):469-82. doi: 10.1177/0961203314556140.

Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011. Tong X1, Spradling PR. J Viral Hepat. 2015 Apr 20. doi: 10.1111/jvh.12414. [Epub ahead of print]

HCV Genotyping from NGS Short Reads and Its Application in Genotype Detection from HCV Mixed Infected Plasma. Qiu P1, Stevens R2, Wei B1, et al. PLoS One. 2015 Apr 1;10(4):e0122082. doi: 10.1371/journal.pone.0122082. eCollection 2015.

Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Brayer SW1, Reddy KR. Expert Rev Gastroenterol Hepatol. 2015 May;9(5):547-58. doi: 10.1586/17474124.2015.1032938. Epub 2015 Apr 6.

LIVER CANCER

3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. Saito M1, Takano T2, Nishimura T3, Kohara M4, Tsukiyama-Kohara K5. PLoS One. 2015 Apr 13;10(4):e0124197. doi: 10.1371/journal.pone.0124197. eCollection 2015.

Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Ali N1,2,3, Chandrakesan P1, Nguyen CB1, et al. Oncotarget. 2015 Apr 29. [Epub ahead of print]

Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. Meguro M1, Mizuguchi T1, Nishidate T1, et al. World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933.

Treg -specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma. Liu HR1, Li WM. IUBMB Life. 2015 Apr 23. doi: 10.1002/iub.1378. [Epub ahead of print]

Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Bamia C1, Lagiou P, Jenab M, et al. Int J Cancer. 2015 Apr 15;136(8):1899-908. doi: 10.1002/ijc.29214. Epub 2014 Sep 24.

Trans-arterial Chemoembolization with Doxorubicin-eluting Particles versus Conventional Trans-arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: a Study of Effectiveness, Safety and Costs. Megías Vericat JE1, García Marcos R2, López Briz E3, et al. Radiologia. 2015 Apr 6. pii: S0033-8338(15)00076-4. doi: 10.1016/j.rx.2015.01.008. [Epub ahead of print]

VEGF in Patients with Advanced Hepatocellular Carcinoma Receiving Intra-arterial Chemotherapy. Matsui D1, Nagai H2, Mukozu T1, Ogino YU1, Sumino Y1. Anticancer Res. 2015 Apr;35(4):2205-10.

The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. Kramer JR1, Kowalkowski MA, Duan Z, Chiao EY. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):456-62. doi: 10.1097/QAI.0000000000000494.

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)